Advances in personalized medicine are helping women and their doctors move beyond one-size-fits-most treatment. PreludeDxTM is leading the way with tools that bring clarity and confidence to breast cancer decisions.
Following a breast cancer diagnosis, women face a maze of choices. For women with ductal carcinoma in situ (DCIS), also known as Stage 0 breast cancer, one of the most urgent questions is whether to undergo radiation after breast-conserving surgery (BCS).
Troy Bremer, Ph.D.
Chief Scientific Officer, PreludeDx
To guide this decision, doctors have historically relied on clinical-pathology checklists that group patients into low or high risk based on population data. “These are soft tools,” explained Troy Bremer, Ph.D., chief scientific officer of PreludeDx. “They don’t give you the precise information needed for a better treatment decision.”
As a result, many women opt for radiation “just in case.” Today as many as 4 in 5 women with DCIS receive radiation after BCS — even though prospective randomized studies show that only about 1 in 7 will benefit.
From pathology checklists to personalized assessments of a woman’s biology
PreludeDx’s DCISionRT® is changing the conversation as the first and only test validated to predict a patient’s individual benefit from radiation therapy after BCS. By leveraging the power of tumor biology, the test provides an individual score ranging from 0 – 10, corresponding to each woman’s risk of recurrence and benefit from radiation therapy.
This clarity has proven transformative: In a large multicenter study, DCISionRT results changed physicians’ recommendations in nearly 40% of cases. The RT treatment decision was changed for 2 in 5 women after receiving their personalized test results.
Dan Forche
CEO, PreludeDx
The test is now ordered by breast surgeons or radiation oncologists in more than 85% of the top 50 U.S. cancer centers. “DCISionRT is becoming the standard of care for physicians and patients throughout the US to properly assess recurrence risk and benefit from RT,” noted Dan Forche, CEO of PreludeDx.
Introducing AidaBreast™: The next generation of insight
Building on that foundation, PreludeDx is launching AidaBreast™, a next-generation test for women with stage I and IIa breast cancer. AidaBreast uses multi-omic technology — analyzing RNA and Protein expression along with Spatial Biology — providing a more complete assessment of a patient’s tumor biology.
“Earlier tests in this space are 20 years old and based solely on RNA,” Bremer explained. “AidaBreast also includes functional proteins that drive the tumor biology as well as the immune response, giving patients and their clinicians the first tool for assessing risk and predicting RT benefit in early-stage invasive breast cancer.”
The first test in the AidaBreast portfolio provides a radiation therapy assessment for early-stage breast cancer, offering the same kind of individualized radiation insight that DCISionRT provides for DCIS. Future modules will expand the platform to include endocrine therapy and chemotherapy assessments, creating a single, integrated tool that helps physicians and patients understand the likely benefit of each therapy option.
Putting knowledge in patients’ hands
Forche emphasized that these advances in personalized diagnostics are about giving patients an informed choice: “Radiation, endocrine therapy, and chemotherapy each come with benefits and side effects. We want to ensure that women have the most comprehensive information available to make a better choice in treatment.”
With DCISionRT already transforming DCIS care and AidaBreast poised to do the same for early invasive breast cancer, PreludeDx is ushering in a new era of precision medicine — one where every woman can feel informed, empowered, and truly seen in her treatment plan.
“Five years from now,” Forche added, “we want to be the one-stop shop by providing women the most comprehensive decision support tools for early-stage breast cancer.”
To learn more, visit preludedx.com
